Related Experiment Video

Updated: Mar 9, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment

Marcus M Mücke1, Victoria T Mücke1, Christian M Lange1

  • 1Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt a.M., Germany.

Liver International : Official Journal of the International Association for the Study of the Liver
|January 5, 2017
PubMed

Insights

Direct-acting antivirals offer high cure rates for hepatitis C. This review examines effective interferon-free treatments for patients with advanced liver or kidney disease, addressing safety and efficacy challenges.

Area of Science:

  • Hepatology and Infectious Diseases
  • Pharmacology and Therapeutics

Background:

  • Direct-acting antivirals (DAAs) have transformed hepatitis C treatment, achieving high sustained virological response (SVR) rates (>95%) in the general population.
  • The aging hepatitis C virus (HCV) population presents challenges, with an increasing number of patients having advanced liver disease (decompensated cirrhosis) or severe renal impairment.
  • Treatment safety and efficacy in these complex patient groups remain significant clinical concerns.

Purpose of the Study:

  • To review the current knowledge on treating hepatitis C in patients with decompensated cirrhosis and severe renal impairment.
  • To present effective interferon-free treatment regimens for these difficult-to-treat populations.
  • To discuss challenges, special considerations, and emerging issues with DAAs in this cohort.

Main Methods:

  • Literature review focusing on direct-acting antiviral (DAA) therapies.
  • Analysis of treatment outcomes, safety profiles, and efficacy in patients with advanced liver and/or renal dysfunction.
  • Synthesis of current clinical guidelines and emerging research on interferon-free regimens.

Main Results:

  • Interferon-free DAA regimens demonstrate favorable SVR rates in patients with decompensated cirrhosis and severe renal impairment.
  • Specific treatment strategies can be tailored to achieve successful outcomes in these challenging patient subgroups.
  • The review identifies key considerations and potential pitfalls associated with DAA use in patients with organ dysfunction.

Conclusions:

  • Hepatitis C can be effectively treated with modern interferon-free regimens even in patients with advanced liver or kidney disease.
  • Careful patient selection and regimen choice are crucial for optimizing safety and efficacy.
  • Ongoing research and clinical vigilance are necessary to address evolving challenges in DAA therapy for complex HCV populations.

Keywords:
decompensated cirrhosishepatitis C virusrenal impairmentspecial populations

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

924

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
549
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
512
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
702